Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

In vitro effectiveness of the antimicrobial peptide eCATH1 against antibiotic-resistant bacterial pathogens of horses.

Schlusselhuber M, Guldbech K, Sevin C, Leippe M, Petry S, Grötzinger J, Giguère S, Cauchard J.

FEMS Microbiol Lett. 2014 Jan;350(2):216-22. doi: 10.1111/1574-6968.12337. Epub 2013 Dec 18.

2.

In vitro potential of equine DEFA1 and eCATH1 as alternative antimicrobial drugs in rhodococcosis treatment.

Schlusselhuber M, Jung S, Bruhn O, Goux D, Leippe M, Leclercq R, Laugier C, Grötzinger J, Cauchard J.

Antimicrob Agents Chemother. 2012 Apr;56(4):1749-55. doi: 10.1128/AAC.05797-11. Epub 2012 Jan 9.

3.

In-vitro susceptibility to antimicrobial drugs of bacterial isolates from horses in The Netherlands.

Ensink JM, van Klingeren B, Houwers DJ, Klein WR, Vulto AG.

Equine Vet J. 1993 Jul;25(4):309-13.

PMID:
8354217
4.
5.

The activity of antimicrobial peptide S-thanatin is independent on multidrug-resistant spectrum of bacteria.

Wu G, Li X, Fan X, Wu H, Wang S, Shen Z, Xi T.

Peptides. 2011 Jun;32(6):1139-45. doi: 10.1016/j.peptides.2011.03.019. Epub 2011 Mar 29.

PMID:
21453736
6.

Activity of the antimicrobial peptide and thanatin analog S-thanatin on clinical isolates of Klebsiella pneumoniae resistant to conventional antibiotics with different structures.

Wu GQ, Ding JX, Li LX, Wang HL, Zhao R, Shen ZL.

Curr Microbiol. 2009 Aug;59(2):147-53. doi: 10.1007/s00284-009-9410-2. Epub 2009 May 21.

PMID:
19459007
7.
8.

Battacin (Octapeptin B5), a new cyclic lipopeptide antibiotic from Paenibacillus tianmuensis active against multidrug-resistant Gram-negative bacteria.

Qian CD, Wu XC, Teng Y, Zhao WP, Li O, Fang SG, Huang ZH, Gao HC.

Antimicrob Agents Chemother. 2012 Mar;56(3):1458-65. doi: 10.1128/AAC.05580-11. Epub 2011 Dec 19.

11.

Determination of the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in Rhodococcus equi isolates and treatment outcome in foals infected with antimicrobial-resistant isolates of R equi.

Giguère S, Lee E, Williams E, Cohen ND, Chaffin MK, Halbert N, Martens RJ, Franklin RP, Clark CC, Slovis NM.

J Am Vet Med Assoc. 2010 Jul 1;237(1):74-81. doi: 10.2460/javma.237.1.74.

PMID:
20590498
14.
15.
16.

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.

Sader HS, Jones RN, Dowzicky MJ, Fritsche TR.

Diagn Microbiol Infect Dis. 2005 Jul;52(3):203-8.

PMID:
16105565
17.

Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections.

Fritsche TR, Rhomberg PR, Sader HS, Jones RN.

J Antimicrob Chemother. 2008 May;61(5):1092-8. doi: 10.1093/jac/dkn074. Epub 2008 Feb 29.

PMID:
18310135
18.

In vitro activity of MSI-78 alone and in combination with antibiotics against bacteria responsible for bloodstream infections in neutropenic patients.

Giacometti A, Cirioni O, Kamysz W, D'Amato G, Silvestri C, Licci A, Nadolski P, Riva A, Lukasiak J, Scalise G.

Int J Antimicrob Agents. 2005 Sep;26(3):235-40.

PMID:
16122911
19.

Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).

Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.

J Antimicrob Chemother. 2006 May;57(5):914-23. Epub 2006 Mar 20.

PMID:
16549511
20.

Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).

Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ.

Int J Antimicrob Agents. 2009 Aug;34(2):121-30. doi: 10.1016/j.ijantimicag.2009.02.003. Epub 2009 Apr 1.

PMID:
19342205

Supplemental Content

Support Center